ThomasEStinchcombeMD

Oncology • Durham, NC

Hematologic Oncology, Thoracic Cancer

Professor of Medicine, Duke University

Join to view full profile

Dr. Stinchcombe is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Stinchcombe's full profile

Already have an account?

Office
20 Duke Medicine Circle
Durham, NC 27710
Phone+1 919-668-6688

Fax+1 919-684-5163
Is this information wrong?

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 1998 - 2001
University of Michigan Health SystemResidency, Internal Medicine, 1995 - 1998
University of Virginia School of MedicineClass of 1995

Certifications & Licensure

NC State Medical License 1998 - 2024
MI State Medical License 1995 - 1998
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer Start of enrollment: 2005 May 01
Terminated
Phase 2
Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC Start of enrollment: 2006 Mar 01
Completed
Phase 2
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors Start of enrollment: 2006 Aug 01
Completed
Phase 1
Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer Start of enrollment: 2006 Apr 01
Terminated
Phase 2
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC Start of enrollment: 2007 Aug 01
Terminated
Phase 2
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2004 Dec 01
Completed
Phase 1
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors Start of enrollment: 2007 Sep 01
Completed
Phase 1
Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab Start of enrollment: 2010 Dec 01
Completed
Phase 2
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers Start of enrollment: 2010 Mar 01
Completed
Phase 2
NCI 8873: Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCL Start of enrollment: 2011 Jun 01
Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations Start of enrollment: 2012 Mar 16
Completed
Phase 2
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors Start of enrollment: 2017 Mar 09
Terminated
Phase 2
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer Start of enrollment: 2017 May 20
Terminated
Phase 2
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations Start of enrollment: 2018 Jun 30
Completed
Phase 2
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Start of enrollment: 2019 Jun 27
Terminated
Phase 1
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2019 Feb 12
Recruiting
Phase 1, Phase 2
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib Start of enrollment: 2020 Jul 09
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

The changing landscape of small cell lung cancer.
Giordano Fabricio Cittolin-Santos, Bharath Ganesh, Feng Gao, Saiama Waqar, Thomas Eldridge Stinchcombe, Ramaswamy Govindan, Daniel Morgensztern, Knapp, B., Brendan Knapp> ;Cancer. 2024 Mar 12
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
Dunne, E., Fick, C., Isbell, J., Chaft, J., Altorki, N., Park, B., Spicer, J., Forde, P., Gomez, D., Iyengar, P., Harpole, D., Stinchcombe, T., Liberman, M., Bott, M.,...> ;The Annals of Thoracic Surgery. 2024 Feb 3
Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-...
Thomas E Stinchcombe, Xiaofei Wang, Bryce Damman, Jennifer Mentlick, Rodney Landreneau, Dennis Wigle, David R Jones, Massimo Conti, Ahmad S Ashrafi, Moishe Liberman, M...> ;Journal of Clinical Oncology. 2024 Apr 1
Convolutional Neural Networks for Segmentation of Malignant Pleural Mesothelioma: Analysis of Probability Map Thresholds (CALGB 30901, Alliance).
Shenouda, M., Gudmundsson, E., Li, F., Wang, X., Starkey, A., Armato, S., Straus, C., Kindler, H., Dudek, A., Stinchcombe, T.> ;Arxiv. 2023 Nov 30
Enrollment Success, Factors, and Prediction Models in Cancer Trials (2008-2019).
Siqi Zhang, Jianrong Zhang, Sida Liu, Herbert Pang, Thomas E Stinchcombe, Xiaofei Wang> ;JCO Oncology Practice. 2023 Nov 1
5 citations
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, Jean-Luc Canon, Matthew D Galsky, Erika Hamilton, Hidetoshi Hayashi, Guy Jerusalem, Seung Tae Kim, Keun-Wook Lee, Lion...> ;Journal of Clinical Oncology. 2023 Dec 20
Selpercatinib in patients withfusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial.
Thomas E Stinchcombe> ;Translational Lung Cancer Research. 2023 Jul 31
4 citations
Lobectomy, segmentectomy, or wedge resection for peripheral clinical T1aN0 non-small cell lung cancer: A post hoc analysis of CALGB 140503 (Alliance).
Nasser Altorki, Xiaofei Wang, Bryce Damman, Jennifer Mentlick, Rodney Landreneau, Dennis Wigle, David R Jones, Massimo Conti, Ahmad S Ashrafi, Moishe Liberman, Marc de...> ;The Journal of Thoracic and Cardiovascular Surgery. 2024 Jan 1
Encorafenib and Binimetinib: A New Treatment Option for-Mutant Non-Small-Cell Lung Cancer.
Thomas E Stinchcombe> ;Journal of Clinical Oncology. 2023 Jul 20
Using a Clinically Interpretable End Point Composed of Multiple Outcomes to Evaluate Totality of Treatment Effect in Comparative Oncology Studies.
Xiaofei Wang, Zachary R McCaw, Lu Tian, Thomas E Stinchcombe, Everett Vokes, Ethan B Ludmir, Lee-Jen Wei> ;JAMA Network Open. 2023 Jun 1
Flashback Foreword: Afatinib for the Treatment of Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer.
Thomas E Stinchcombe> ;Journal of Clinical Oncology. 2023 Jun 1
1 citations
Flashback Foreword: Docetaxel Versus Best Supportive Care in Non-Small-Cell Lung Cancer and Pemetrexed Versus Docetaxel in Second-Line Non-Small-Cell Lung Cancer.
Thomas E Stinchcombe> ;Journal of Clinical Oncology. 2023 May 20
Flashback Foreword: Cisplatin/Pemetrexed in Non-Small-Cell Lung Cancer.
Thomas E Stinchcombe> ;Journal of Clinical Oncology. 2023 May 10
Flashback Foreword: Bevacizumab + Carboplatin/Paclitaxel in NSCLC.
Thomas E Stinchcombe> ;Journal of Clinical Oncology. 2023 May 1
Flashback Foreword: Pemetrexed and Cisplatin in Mesothelioma.
Thomas E Stinchcombe> ;Journal of Clinical Oncology. 2023 Apr 20
Flashback Foreword: Gefitinib in Non-Small-Cell Lung Cancer: The IDEAL 1 Trial.
Thomas E Stinchcombe> ;Journal of Clinical Oncology. 2023 Feb 20
2 citations
Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver.
Thomas E Stinchcombe> ;Translational Lung Cancer Research. 2023 Jan 31
12 citations
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
Jeffrey Bogart, Xiaofei Wang, Gregory Masters, Junheng Gao, Ritsuko Komaki, Laurie E Gaspar, John Heymach, James Bonner, Charles Kuzma, Saiama Waqar, William Petty, Th...> ;Journal of Clinical Oncology. 2023 May 1
1 citations
Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.
Monica H Bodd, Susan C Locke, Steve P Wolf, Scott Antonia, Jeffrey Crawford, John Hartman, Kris W Herring, Neal E Ready, Thomas E Stinchcombe, Jesse D Troy, Chakita Wi...> ;Lung Cancer. 2023 Jan 1
Characteristics of toxicity occurrence patterns in concurrent chemoradiotherapy after induction chemotherapy for patients with locally advanced non-small cell lung can...
Lexie Zidanyue Yang, Qihua He, Jianrong Zhang, Apar Kishor Ganti, Thomas E Stinchcombe, Herbert Pang, Xiaofei Wang> ;Translational Cancer Research. 2022 Oct 1
10 citations
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung ...
Steven E Schild, Xiaofei Wang, Christine M Bestvina, Terence Williams, Greg Masters, Anurag K Singh, Thomas E Stinchcombe, Joseph K Salama, Steven Wolf, Tyler Zemla, N...> ;Clinical Lung Cancer. 2022 Jul 1
1 citations
A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial.
Jeffrey M Clarke, Lin Gu, Xiaofei F Wang, Thomas E Stinchcombe, Marvaretta M Stevenson, Sundhar Ramalingam, Afreen Shariff, Jennifer Garst, Andrew B Nixon, Scott J Ant...> ;JTO Clinical and Research Reports. 2022 Jun 1
7 citations
Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
James Isaacs, Thomas E Stinchcombe> ;Drugs. 2022 Jun 1
25 citations
Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).
Kenneth L Kehl, David Zahrieh, Ping Yang, Shauna L Hillman, Angelina D Tan, Jacob M Sands, Geoffrey R Oxnard, Erin A Gillaspie, Dennis Wigle, Shakun Malik, Thomas E St...> ;JAMA Oncology. 2022 May 1
1 citations
Thoracic Oncology: Current Standard Therapy and Future Developments.
Thomas E Stinchcombe, Jeffrey D Bradley> ;Journal of Clinical Oncology. 2022 Feb 20
Join now to see all

Press Mentions

Bevacizumab-Erlotinib Combo Falls Short in EGFR-Mutant Advanced NSCLCAugust 12th, 2019
Considerations in the Management of ALK+ NSCLCAugust 7th, 2019
Targeted Therapy for ALK+ NSCLCJuly 31st, 2019
Join now to see all

Grant Support

Clinical Trial: Phase I Trial Of Abraxane In Combination With Gemcitabine In SolNational Center For Research Resources2008
Clinical Trial: Cisplatin/Etoposide Or Carboplatin/Pemetrexed In Patients With SNational Center For Research Resources2008
Phase I Trial Of Abraxane In Combination With Gemcitabine In Solid TumorsNational Center For Research Resources2007
Lccc 0412: Phase I Carboplatin And Abraxane In Patients With Solid TumorsNational Center For Research Resources2006–2007